Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
RGNX
#2557
REGENXBIO Inc.
9.040
0
+8.00%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
+8.00%
Monatliche Änderung
-5.88%
6 month change
-32.69%
Jahresänderung
-32.69%
Vorheriger Schlusskurs
8.370
0
Open
9.040
0
Bid
Ask
Low
9.040
0
High
9.040
0
Volumen
78
Märkte
Aktien
Gesundheitswesen
RGNX
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
42.5 M
42.95 M
43.46 M
44.43 M
50.09 M
—
Valuation ratios
Enterprise value
1.59 B
1.06 B
870.11 M
780.28 M
329.64 M
1.32 B
Price to earnings ratio
-15.22
11.24
-3.42
-3.05
-1.68
-9.2
Price to sales ratio
10.94
3.05
8.52
8.89
4.89
12.97
Price to cash flow ratio
31.28
6.56
4.63
3.67
2.21
14.07
Price to book ratio
4.48
1.88
1.86
2.57
1.47
2.72
Enterprise value to EBITDA ratio
41.99
3.3
-19.46
-13.65
-5.56
—
Profitability ratios
Return on assets %
0.16
0.11
0.34
0.46
0.49
0.36
Return on equity %
0.29
0.17
0.54
0.85
0.87
0.93
Return on invested capital %
226.49
126.79
177.57
257.21
402.58
—
Gross margin %
71.91
88.43
51.61
58.76
50.76
346.65
Operating margin %
77.14
34.01
233.2
297.12
297.91
728.3
EBITDA margin %
24.49
68.28
-39.67
-63.37
-75.71
—
Net margin %
71.98
27.18
248.68
291.99
289.94
788.25
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
6.52
3.98
3.19
2.57
2.69
11.42
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.26
0.52
0.12
0.13
0.15
0.32
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
1.45
4.98
4.81
4.99
3.5
2.03
EBIT per share
1.04
7.45
-0.93
-1.29
-1.11
—
EBITDA per share
1.02
7.31
-1.04
-1.31
-1.2
—
Total debt per share
—
—
—
—
—
—
Cash per share
14.02
19.34
13.1
7.18
4.95
23.15
Net current asset value per share
14.25
11.81
9.64
7.66
5.62
25.39
Tangible book value per share
10.13
17.4
11.96
7.13
5.24
17.85
Working capital per share
12.06
8.84
6.62
4.68
3.53
16.5
Book value per share
10.13
17.4
11.96
7.13
5.24
17.85
Nachrichten
Stifel bewertet uniQure nach Äußerungen des FDA-Commissioners zu seltenen Krankheiten
Stifel comments on uniQure shares after FDA commissioner remarks
Uniqure Plummets As FDA's Marty Makary Disparages Rejected Rare Disease Drug
Regenxbio (RGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Is the SPDR S&P Biotech ETF (XBI) a ‘Strong Buy’ Right Now? - TipRanks.com
REGENXBIO: Cautiously Bullish After FDA Setbacks (NASDAQ:RGNX)
Regenxbio: H.C. Wainwright senkt Kursziel nach FDA-Ablehnung auf 32 US-Dollar
Regenxbio stock price target lowered to $32 at H.C. Wainwright after FDA rejection
Intel, Wells Fargo among market cap stock movers on Tuesday
Netflix and Oracle among market cap stock movers on Tuesday
Regenxbio: Goldman Sachs senkt Kursziel nach Rückschlag bei RGX-121
Regenxbio stock price target lowered by Goldman Sachs on RGX-121 setback